Oncogenes and Human Lung Cancer

  • Sjoerd Rodenhuis
Part of the Cancer Treatment and Research book series (CTAR, volume 45)


Despite intensive clinical research efforts of the past 15 years, little real progress has been made in the management of lung cancer, and the outlook for patients whose tumors cannot be completely resected remains grim. Obviously, the surgical and radiotherapeutic treatment modalities are approaching the limits of their potential efficacies, and the early promise of combination chemotherapy has only partially been realized. New cytotoxic agents with significant activity in lung cancer are difficult to find, and the results of early clinical trials with biological agents such as the interferons or interleukins raise little hope of major activity.


Small Cell Lung Cancer Human Lung Cancer Small Cell Lung Cancer Cell Cell Lung Cancer Cell Line Human Small Cell Lung Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47:1473–1487, 1987.PubMedGoogle Scholar
  2. 2.
    Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW, Bertness V, Hollis GF, Minna JD: L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (Lond) 318:69–73, 1985.CrossRefGoogle Scholar
  3. 3.
    Land H, Parada LF, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 222:771–778, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Varmus HE: The molecular genetics of cellular oncogenes. Ann Rev Genet 18:553–612, 1984.PubMedCrossRefGoogle Scholar
  5. 5.
    Weiss R, Marshall CJ: Oncogenes. Lancet 2:1138–1142, 1984.Google Scholar
  6. 6.
    Schimke RT: Gene amplification, drug resistance, and cancer. Cancer Res 44:1735–1742, 1984.PubMedGoogle Scholar
  7. 7.
    Alitalo K, Schwab M: Oncogene amplification in tumor cells. Adv Cancer Res 47:235–281, 1986.PubMedCrossRefGoogle Scholar
  8. 8.
    Brodeur GM, Seeger RC, Schwab M, Varmus H, Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124, 1984.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandberg AA, Gemmil RM, Hecht BK, Hecht F: The Philadelphia chromosome: a model of cancer and molecular cytogenetics. Cancer Genet Cytogenet 21:129–146. 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Bos JL: The ras gene family and human carcinogenesis. Mutation Res 195:255–271, 1988.PubMedGoogle Scholar
  11. 11.
    Southern EM: Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503–517, 1975.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldfarb M, Shimizu K, Perucho M, Wigler M: Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296:404–409, 1982.PubMedCrossRefGoogle Scholar
  13. 13.
    Bos JL, Verlaan-de Vries M, Jansen AM, Veeneman GH, Van Boom JH, Van der Eb AJ: Three different mutations in codon 61 of the human N-ras gene detected by synthetic oligonucleotide hybridization. Nucleic Acids Res 12:9155–9163, 1984.PubMedCrossRefGoogle Scholar
  14. 14.
    Verlaan-de Vries M, Boogaard ME, Van den Elst H, Van Boom JH, Van der Eb AJ, Bos JL: A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxy-nucleotides. Gene 50:313–320, 1986.PubMedCrossRefGoogle Scholar
  15. 15.
    Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, Leder P: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 79:7837–7841, 1982.PubMedCrossRefGoogle Scholar
  16. 16.
    Grady-Leopardi EF, Schwab M, Ablin AR, Rosenau W: Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome. Cancer Res 46:3196–3199, 1986.PubMedGoogle Scholar
  17. 17.
    Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD: Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature (Lond) 306:194–196, 1983.CrossRefGoogle Scholar
  18. 18.
    Gazdar AF, Carney DN, Nau MM, Minna JD: Characterization of variant subclasses of cell lines derived from small cell lung cancer having distictive biochemical, morphological, and growth properties. Cancer Res 45:2924–2930, 1985.PubMedGoogle Scholar
  19. 19.
    Brooks BJ Jr, Battey J, Nau MM, Gazdar AF, Minna JD: Amplification and expression of the myc gene in small-cell lung cancer. Adv Vir Oncol 7:155–172, 1987.Google Scholar
  20. 20.
    Buys CHCM, Osinga J, Van der Veen AY, Mooibroek H, Van der Hout AH, De Leij L, Postmus PE, Carrit B: Genome analysis of small cell lung cancer (SCLC) and clinical significance. Eur J Respir Dis 70 (Suppl 149):29–36, 1987.Google Scholar
  21. 21.
    Ibson JM, Waters JJ, Twentyman PR, Bleehen NM, Rabbitts PH: Oncogene amplification and chromosomal abnormalities in small cell lung cancer. J Cell Biochem 33:267–288, 1987.PubMedCrossRefGoogle Scholar
  22. 22.
    Johnson BE, Battey J, Linnoila I, Becker KL, Makuch RW, Snider RH, Carney DN, Minna JD: Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. J Clin Invest 78:525–532, 1986.PubMedCrossRefGoogle Scholar
  23. 23.
    Kiefer PE, Bepler G, Kubasch M, Havemann K: Amplification and expression of proto-oncogenes in human small cell lung cancer cell lines. Cancer Res 47:6236–6242, 1987.PubMedGoogle Scholar
  24. 24.
    Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER: The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41:665–676, 1985.PubMedCrossRefGoogle Scholar
  25. 25.
    Minna JD, Battey JF, Brooks BJ, Cuttitta F, Gazdar AF, Johnson BE, Ihde DC, Lebacq-Verheyden AM, Mulshine J, Nau MM, Oie HK, Sausville EA, Seifter E, Vinocour M: Molecular genetic analysis reveals chromosomal deletion, gene amplification, and autocrine growth factor production in the pathogenesis of human lung cancer. Cold Spring Harbor Symp Quant Biol LL:843–853, 1986.Google Scholar
  26. 26.
    Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H, Russel E, Nau MM, Minna JD: Myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79:1629–1634, 1987.PubMedCrossRefGoogle Scholar
  27. 27.
    Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B: Gene amplification of c-myc and N-myc in small cell lung carcinoma of the lung. Science 233:461–464, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Funa K, Steinholtz L, Nou E, Bergh J: Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. Am J Clin Path 88:216–220, 1987.PubMedGoogle Scholar
  29. 29.
    Yoshimoto K, Shiraishi M, Hirohashi S, Morinaga S, Shimosato Y, Sugimura T, Sekiya T: Rearrangement of the c-myc gene in two giant cell carcinomas of the lung. Jpn J Cancer Res (Gann) 77:731–735, 1986.Google Scholar
  30. 30.
    Saksela K, Bergh J, Nilsson K: Amplification of the N-myc oncogene in an adenocarcinoma of the lung. J Cell Biochem 31:297–304, 1986.PubMedCrossRefGoogle Scholar
  31. 31.
    Cline MJ, Battifora H: Abnormalities of protooncogenes in non-small cell lung cancer. Correlations with tumor type and clinical characteristics. Cancer 60:2669–2674, 1987.PubMedCrossRefGoogle Scholar
  32. 32.
    Griffin CA, Baylin SB: Expression of the c-myb oncogene in human small cell lung carcinoma. Cancer Res 45:272–275, 1985.PubMedGoogle Scholar
  33. 33.
    Vinocour M, Minna JD: Myc and p53 oncogene expression in human lung cancer cell lines. Feration Proc 46:740 (abstract), 1987.Google Scholar
  34. 34.
    Chan SYT, Evan GI, Ritson A, Watson J, Wraight P, Sikora K: Localization of lung cancer by a radiolabeled monoclonal antibody against the c-mvc oncogene product. Br J Cancer 54:761–769, 1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Barbacid M: Human oncogenes. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds.): Important Advances in Oncology 1986. Philadelphia, J.B. Lippinocott, 1986, pp 3–22.Google Scholar
  36. 36.
    Sistonen L, Alitalo K: Activation of c-ras oncogenes by mutations and amplification. Ann Clin Res 18:297–303, 1986.PubMedGoogle Scholar
  37. 37.
    Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M: Ras gene amplification and malignant transformation. Mol Cell Biol 5:2836–2841, 1985.PubMedGoogle Scholar
  38. 38.
    Valenzuela DM, Groffen J: Four human carcinoma cell lines with novel mutations in position 12 of the c-K-ras oncogene. Nucleic Acids Res 14:843–852, 1986.PubMedCrossRefGoogle Scholar
  39. 39.
    Santos E, Martin-Zanca D, Reddy EP, Pierotti MA, Delia Porta G, Barbacid M: Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223:661–664, 1984.PubMedCrossRefGoogle Scholar
  40. 40.
    Milici A, Blick M, Murphy E, Gutterman JU: c-K-ras codon 12 GGT-CGT point mutation: an infrequent event in human lung cancer. Biochem Biophys Res Comm 140:699–705, 1986.PubMedCrossRefGoogle Scholar
  41. 41.
    Rodenhuis S, Van de Wetering ML, Mooi WJ, Evers SG, Van Zandwijk N, Bos JL: Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929–935, 1987.PubMedCrossRefGoogle Scholar
  42. 42.
    Heighway J, Hasleton PS: c-Ki-ras amplification in human lung cancer. Br J Cancer 53:285–287, 1986.PubMedCrossRefGoogle Scholar
  43. 43.
    Barbacid M: Mutagens, oncogens and cancer. Trends Genet 2:188–192, 1986.CrossRefGoogle Scholar
  44. 44.
    Eva A, Trimmer RW: High frequency of c-K-ras activation in 3-methylcholantrene-induced mouse thymomas. Carcinogenesis 7:1931–1933, 1986.PubMedCrossRefGoogle Scholar
  45. 45.
    Frazier ME, Lindberg RA, Mueller DM, Gee A, Seed TM: Oncogene involvement in plutonium induced carcinogenesis. Workshop on Cell Transformation in Radiobiology. Int J Rad Biol 49:524–543, 1986.Google Scholar
  46. 46.
    Stowers SJ, Glover PL, Reynolds SH, Boone LR, Maronpot RR, Anderson MW: Activation of the K-ras protooncogene in lung tumors from rats and mice chronically exposed to tetranitromethane. Cancer Res 47:3212–3219, 1987.PubMedGoogle Scholar
  47. 47.
    McMahon G, Hanson L, Lee JJ, Wogan GN: Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin Bl. Proc Natl Acad Sci USA 83:9418–9422, 1986.PubMedCrossRefGoogle Scholar
  48. 48.
    Sakiyama S; Nakamura Y, Yasuda S: Expression of epidermal growth factor receptor gene in cultured human lung cancer cells. Jpn J Cancer Res (Gann) 77:965–969, 1986.Google Scholar
  49. 49.
    Lee JS, Blick M, Milici A, Gutterman J: Enhanced expression of the epidermal growth factor receptor gene without gene amplification in uncultured non-small cell lung cancer. Proc Am Assoc Cancer Res 28:20 (abstract 78), 1987.Google Scholar
  50. 50.
    Lee WH, Shew JY, Hong FD, Sery TW, Donoso LA, Young LJ, Bookstein R, Lee EYHP: The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature (Lond) 329:642–645, 1987.CrossRefGoogle Scholar
  51. 51.
    Wurster-Hill DH, Cannizarro LA, Pettengill OS, Sorenson GD, Cate CC, Maurer LH: Cytogenetics of small cell carcinoma of the lung. Cancer Genet Cytogenet 13:303–330, 1984.PubMedCrossRefGoogle Scholar
  52. 52.
    Whang-Peng J, Lee EC: Cytogenetics of human small cell lung cancer. Recent Results Cancer Res 97:37–46, 1985.PubMedGoogle Scholar
  53. 53.
    Sozzi G, Bertoglio MG, Borrello MG, Giani S, Pilotti S, Pierotti M, Delia Porta G: Chromosomal abnormalities in a primary small cell lung cancer. Cancer Genet Cytogenet 27:45–50, 1987.PubMedCrossRefGoogle Scholar
  54. 54.
    Morstyn G, Brown J, Novak U, Gardner J, Bishop J, Garson M: Heterogeneous cytogenetic abnormalities in small cell lung cancer cell lines. Cancer Res 47:3322–3327, 1987.PubMedGoogle Scholar
  55. 55.
    Mooibroek H, Osinga J, Postmus PE, Carrit B, Buys CHCM: Loss of heterozygosity for a chromosome 3 sequence presumably at 3p21 in small cell lung cancer. Cancer Genet Cytogenet 27:361–365, 1987.PubMedCrossRefGoogle Scholar
  56. 56.
    Mitelman F: Catalog of Chromosome Alterations in Cancer. Second edition. New York, Alan Liss, Inc., 1985, pp 61–88.Google Scholar
  57. 57.
    Brauch H, Johnson B, Hovis J, Yano T, Gazdar A, Pettengill OS, Graziano S, Sorenson GD, Poiesz BJ, Minna JD, Linehan M, Zbar B: Molecular analysis of the short arm of chromosome 3 in small-cell and non-small cell carcinoma of the lung. Engl J Med 317: 1109–1113, 1987.CrossRefGoogle Scholar
  58. 58.
    Kok K, Osinga J, Carritt B, Davis MB, Van der Hout AH, Van der Veen AY, Landsvater RM, De Leij LFMH, Berendsen HH, Postmus PE, Poppema S, Buys CHCM: Deletion of a DNA sequence at the chromosomal 3p21 in all major types of lung cancer. Nature 330:578–581, 1987.PubMedCrossRefGoogle Scholar
  59. 59.
    Naylor SL, Johnson BE, Minna JD, Sakaguchi AY: Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature (Lond) 329:451–454, 1987.CrossRefGoogle Scholar
  60. 60.
    Zbar B, Brauch H, Talmadge C, Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721–724, 1987.PubMedCrossRefGoogle Scholar
  61. 61.
    Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL: Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer 55:513–516, 1987.PubMedCrossRefGoogle Scholar
  62. 62.
    Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74:647–651, 1984.PubMedCrossRefGoogle Scholar
  63. 63.
    Mendelsohn J, Divgi C, Yeh S, Masui H, Gralla R, Kris M, Real F, Unger M, Schweighardt S, Bartholomew R, David G, Goldenberg A, Welt S:Phase I clinical trial with anti-EGF receptor monoclonal antibody. Proc. 6th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam March 7–10 1989, abstract 151.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1989

Authors and Affiliations

  • Sjoerd Rodenhuis

There are no affiliations available

Personalised recommendations